Pulmonary Arterial Hypertension Clinical Trials in Durham, North Carolina

8 studies are recruiting for pulmonary arterial hypertension in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

   Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) tre…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duke University Medical Center ( Site 1026), Durham, North Carolina

   Locations

   136 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07218029 on ClinicalTrials.gov

2. An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

   This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   Duke University, Durham, North Carolina

   Locations

   43 in total

   Run by

   Inhibikase Therapeutics

   See if you can join NCT07365332 on ClinicalTrials.gov

3. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

   The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

   Stage

   Not phased

   Ages

   0 to 20

   Site

   Duke University Health System, Durham, North Carolina

   Locations

   52 in total

   Run by

   Duke University

   See if you can join NCT04278404 on ClinicalTrials.gov

4. Xenon MRI Pulm Hypertension

   The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or t…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Duke University Medical Center, Durham, North Carolina

   Run by

   Bastiaan Driehuys

   See if you can join NCT04991454 on ClinicalTrials.gov

5. Pulmonary Hypertension SOLAR

   The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signat…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Run by

   Bastiaan Driehuys

   See if you can join NCT04778046 on ClinicalTrials.gov

6. 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

   The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of addit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Duke University Medical Center, Durham, North Carolina

   Run by

   Bastiaan Driehuys

   See if you can join NCT06104228 on ClinicalTrials.gov

7. 129 Xenon Imaging in Patients Treated With Sotatercept

   Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Duke University Medical Center, Durham, North Carolina

   Run by

   Bastiaan Driehuys

   See if you can join NCT06351345 on ClinicalTrials.gov

8. Pulmonary Hypertension Association Registry

   The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care C…

   Stage

   Not phased

   Ages

   0 and older

   Site

   Duke University Medical Center, Durham, North Carolina

   Locations

   52 in total

   Run by

   Pulmonary Hypertension Association, Inc.

   See if you can join NCT04071327 on ClinicalTrials.gov